TB500 & BPC-157 10mg

TB-500 & BPC-157 10mg Research Peptide

TB-500 & BPC-157 10mg is a combined research peptide formulation containing TB-500 and BPC-157, designed exclusively for laboratory, analytical, and scientific research applications.

TB-500 is associated with the thymosin beta-4 fragment LKKTETQ, while BPC-157 is a synthetic peptide frequently investigated in experimental and biochemical research models. This combined formulation may be used by qualified researchers for controlled investigations involving peptide chemistry and molecular characterization.

Potential laboratory research applications include:

• Peptide identity and characterization
• Molecular interaction studies
• Analytical method development
• Peptide stability research
• Biochemical pathway investigations
• In-vitro laboratory models
• Comparative peptide analysis
• Research assay development
• Peptide purity and composition analysis

Product Information

• Product: TB-500 & BPC-157
• Labeled Strength: 10mg
• Format: Combined research peptide formulation
• Product Type: Synthetic research peptides
• Research Area: Peptide and biochemical research
• Intended Setting: Laboratory and scientific research
• Supplier: Peptides R US

Research Use Only

This product is offered solely for legitimate laboratory, analytical, and scientific research purposes.

It is not intended for human or veterinary consumption or administration and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

No dosage, injection, reconstitution-for-human-use, therapeutic, or clinical instructions are provided or implied.

FDA currently identifies safety concerns surrounding compounded products containing BPC-157 and the TB-500/thymosin beta-4 fragment, including limited human safety information and potential issues involving immunogenicity and peptide-related impurities. FDA has also specifically reviewed BPC-157- and TB-500-related bulk drug substances through its 2026 Pharmacy Compounding Advisory Committee process; that review should not be interpreted as FDA approval of these substances for human use.